SCHEMBL2009888

SCHEMBL2009888

CC(C)(C)OC(=O)NCC(=O)c1ccc(OCc2ccccc2)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 2/20 0.55
MAOB P27338 1/20 0.55
NR4A1 P22736 1/20 0.54
NR4A2 P43354 1/20 0.54
NR4A3 Q92570 1/20 0.54
EGFR P00533 2/20 0.53
PARP10 Q53GL7 1/20 0.51
RAB9A P51151 2/20 0.51
SMN1; SMN2 Q16637 2/20 0.51
MAPT P10636 2/20 0.51
ALDH1A1 P00352 1/20 0.51
GAA P10253 1/20 0.51
HTT P42858 1/20 0.51
SRD5A2 P31213 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
NPC1 O15118 1/20 0.50
HDAC3 O15379 1/20 0.49
HDAC2 Q92769 1/20 0.49
NCOR2 Q9Y618 1/20 0.49
ADRB2 P07550 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2013045 0.89 SMN1; SMN2 (0.49) HDAC1MAOBEGFRRAB9ASMN1; SMN2
SCHEMBL2009205 0.84 SMN1; SMN2 (0.51) RAB9ASMN1; SMN2MAPTALDH1A1NPC1
SCHEMBL749687 0.84 HDAC1 (0.60) HDAC1MAOBNR4A1NR4A2NR4A3
SCHEMBL6428058 0.84 ALOX5 (0.52) HDAC1MAOBNR4A1NR4A2NR4A3
SCHEMBL941121 0.84 JAK3 (0.48) RAB9ASMN1; SMN2MAPTALDH1A1NPC1
SCHEMBL596575 0.83 HDAC1 (0.67) HDAC1MAOBRAB9ASMN1; SMN2NPC1
SCHEMBL7043590 0.83 LTA4H (0.62) RAB9ASMN1; SMN2ALDH1A1NPC1MEN1
SCHEMBL27396445 0.83 MAOB (0.66) HDAC1MAOBNR4A1NR4A2NR4A3
SCHEMBL864308 0.82 HDAC1 (0.61) HDAC1MAOBNR4A1NR4A2NR4A3
SCHEMBL25623328 0.82 CA12 (0.62) HDAC1RAB9ASMN1; SMN2MAPTL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025244832-A1 NOVEL AMINOGUANIDINE DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF KONG'S PHARMACEUTICAL CO. (US) 2025-11-27 WO disclosed
WO-2011105572-A1 NOVEL HETEROARYL DERIVATIVE 持田製薬株式会社 (JP) 2011-09-01 WO disclosed
US-7964628-B2 Fibrinogen receptor antagonists and their use PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-06-21 US disclosed
US-20100256161-A1 FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE PIRAMAL LIFE SCIENCES LIMITED (IN) 2010-10-07 US disclosed
US-7759387-B2 Fibrinogen receptor antagonists and their use PIRAMAL LIFE SCIENCES LIMITED (IN) 2010-07-20 US disclosed
US-20070021489-A1 Fibrinogen receptor antagonists and their use NICHOLAS PIRAMAL INDIA LIMITED (IN) 2007-01-25 US disclosed
EP-1677783-A2 FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE Nicholas Piramal India Limited (IN) 2006-07-12 EP disclosed
WO-2005035495-A2 FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE NICHOLAS PIRAMAL INDIA LIMITED (IN) 2005-04-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256161-A1 FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE FGB, F13B, F2 HDAC1 3447/4885MAOB 1394/4885NR4A1 733/4885
US-20070021489-A1 Fibrinogen receptor antagonists and their use FGB, F13B, F2 HDAC1 3447/4885MAOB 1394/4885NR4A1 733/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.